Cover Image
市場調查報告書

Pulmicort(氣喘):市場預測與分析

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316072
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
Pulmicort(氣喘):市場預測與分析 Pulmicort (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 53 Pages
簡介

Pulmicort是由AstraZeneca在1997年所開發的ICS(吸入用類固醇藥)治療方法,用於預防及幼兒期·成人期的氣喘維持治療上。活性物質Budesonide是具有抗發炎效果的皮質類固醇,與其受體具有高度親和性。AstraZeneca銷售的Pulmicort衍生產品有Flexhaler(成人及6歲以上患者用)和Pulmicort Respules(1∼8歲的幼兒用)、Pulmicort Turbuhaler(支氣管氣喘患者用)等。

本報告提供氣喘治療藥之一──Pulmicort的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,Pulmicort的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定公開的相關報告

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療指南,臨床診療及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭評估

第6章 Pulmicort(Budesonide)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Pulmicort (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

AstraZeneca's Pulmicort is an ICS therapy that was originally launched in 1997, and is used prophylactically for the maintenance treatment of asthma in children and adults. Its active ingredient, budesonide, is an anti-inflammatory corticosteroid with a high affinity for the corticosteroid receptor. AstraZeneca's Pulmicort franchise includes the Pulmicort Flexhaler (budesonide) for adults and pediatric patients older than six years of age, Pulmicort Respules for children between one and eight years of age, and the Pulmicort Turbuhaler for patients with bronchial asthma.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Pulmicort including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Pulmicort for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Pulmicort performance
  • Obtain sales forecast for Pulmicort from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Pulmicort (budesonide)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Pulmicort
  • Table 8: Pulmicort-Associated Adverse Events
  • Table 9: Pulmicort SWOT Analysis, 2014
  • Table 10: Global Sales Forecast ($) for Pulmicort, 2013-2023
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top